Semaglutide
US$ 22.39
glp-1 crohn's disease Role of glucagon-like peptides in inflammatory bowel diseases—current knowledge and future perspectives | Naunyn-Schmiedeberg's Archives of Pharmacology Ozempic and Crohn's Disease: Could
Description
[DOI] [PubMed] [Google Scholar] 69.ONeil PM, et al
From the non-GLP RA group, 2,332,778 were excluded, resulting in 9,103,212 patients
Glycemic effects remain relevant, particularly in patients with prediabetes or insulin resistance, but they are no longer the defining measure of success
And increasingly, GLP-1s are no longer just about controlling blood sugar
The GLP-1 diabetes treatment drugs market is expected to grow at a 25.3% CAGR between 2025 and 2035
